Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496), has announced the publication of clinical trial results for its dual-target bispecific antibody drug M701, which targets Ep CAM and CD3, in treating malignant ascites caused by advanced epithelial tumors. This recognition by an international medical journal signifies the clinical value of the innovative therapy [1]. Group 1: Clinical Trial Results - The Phase II study aimed to evaluate the efficacy and safety of M701 administered via intraperitoneal infusion in patients with moderate to severe malignant ascites due to advanced epithelial tumors [1]. - A total of 84 patients were enrolled in the study, with 43 patients assigned to the M701 group, who received abdominal puncture and M701 infusion [1]. - The median puncture-free survival time for the M701 group was 75 days, compared to 25 days for the control group, showing a significant difference (p=0.0065) [1]. Group 2: Efficacy Across Cancer Types - Subgroup analysis indicated that various cancer types, including gastric cancer, colorectal cancer, and ovarian cancer, benefited from M701 infusion [1]. - Patients with a baseline relative lymphocyte count of ≥13% experienced better efficacy from the treatment [1]. - The overall survival time for patients in the M701 group was extended compared to the control group, with 6-month survival rates of 33.3% for the M701 group versus 12.1% for the control group [1]. Group 3: Safety Profile - No serious adverse events were observed in the M701 group during the study [1].
友芝友生物-B(02496)于《实验血液学与肿瘤学》上发表M 701恶性腹水II期数据